AstraZeneca to present new cardiovascular data on Farxiga in type-2 diabetes at ACC 2019
First sub-analyses from Phase III DECLARE-TIMI 58 trial selected for late-breaking clinical trial and oral presentationsData evaluating the cardiovascular (CV) effects of Farxiga (dapagliflozin), including hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on 16-18 March. The data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for Farxiga. AstraZeneca will also present the latest results from